Legend Biotech Corp ADR (NASDAQ: LEGN) on Friday, plunged -0.51% from the previous trading day, before settling in for the closing price of $43.09. Within the past 52 weeks, LEGN’s price has moved between $38.60 and $70.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 50.60% annually for the last half of the decade. The company achieved an average annual earnings per share of 39.27%. With a float of $181.45 million, this company’s outstanding shares have now reached $181.91 million.
In an organization with 1826 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 56.67%, operating margin of -76.29%, and the pretax margin is -62.95%.
Legend Biotech Corp ADR (LEGN) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Legend Biotech Corp ADR is 0.94%, while institutional ownership is 50.05%. The most recent insider transaction that took place on Sep 25 ’24, was worth 66,326. Before that another transaction happened on Sep 20 ’24, when Company’s Officer proposed sale 90,060 for $48.91, making the entire transaction worth $4,405,003.
Legend Biotech Corp ADR (LEGN) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 39.27% per share during the next fiscal year.
Legend Biotech Corp ADR (NASDAQ: LEGN) Trading Performance Indicators
Legend Biotech Corp ADR (LEGN) is currently performing well based on its current performance indicators. A quick ratio of 4.78 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.57, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -0.50 in one year’s time.
Technical Analysis of Legend Biotech Corp ADR (LEGN)
Let’s dig in a bit further. During the last 5-days, its volume was 2.6 million. That was better than the volume of 1.05 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 7.90%. Additionally, its Average True Range was 2.46.
During the past 100 days, Legend Biotech Corp ADR’s (LEGN) raw stochastic average was set at 19.17%, which indicates a significant increase from 8.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.69% in the past 14 days, which was lower than the 52.22% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $51.40, while its 200-day Moving Average is $52.71. However, in the short run, Legend Biotech Corp ADR’s stock first resistance to watch stands at $43.67. Second resistance stands at $44.47. The third major resistance level sits at $45.30. If the price goes on to break the first support level at $42.04, it is likely to go to the next support level at $41.20. The third support level lies at $40.40 if the price breaches the second support level.
Legend Biotech Corp ADR (NASDAQ: LEGN) Key Stats
Market capitalization of the company is 7.85 billion based on 182,283K outstanding shares. Right now, sales total 285,140 K and income totals -518,250 K. The company made 186,520 K in profit during its latest quarter, and -18,200 K in sales during its previous quarter.
